Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

1
Player Avatar zzlangerhans (99.81) Submitted: 2/12/2013 2:30:38 AM : Underperform Start Price: $10.45 SNTA Score: +9.83

Too much too soon for Synta, a stock enjoying the 2013 biopharma rocket effect. Ganetespib has proven very little so far, and certainly not enough to justify a 650M market cap. Management has been taking full advantage of the precipitous increase in stock value with dilutive financings to ensure that their salaries will be around for years even of ganetespib fails miserably. We shouldn't have much longer to wait with topline PFS and OS data from the phase II portion of the GALAXY trial of ganetespib in advanced NSCLC expected later this year. I'm expecting a heavy emphasis on subset analyses.

Featured Broker Partners


Advertisement